MantaBio

MantaBio's device automates microbial contamination detection in drug manufacturing. Legacy contamination detection takes 5-28 days - we do it in <2hrs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded February 2025
  • Employees 8
  • Incorporation Type C-corp
  • Website mantabio.com

Company Summary

MantaBio creates a device used for microbial contamination detection in drug manufacturing. Legacy contamination detection takes 5-28 days - we do it in $100M/ batch in conserved resources and avoidance of lost revenue, FDA fines, cleaning fees, recall fees.

Team

  • Co-Founder & President

    Carter Boisfontaine (President): $500M+ in transactions, in both VC investments and fundraising for startups. At Pegasus Tech Ventures, which has $2B in AUM and 40+ corporate partners, Carter led their $1B growth fund with the founding partner. At Bird Global, Carter and his Corporate Development team played a pivotal role in closing $200M in private financing, a $150M Apollo debt facility, a SPAC deal, and managing two acquisitions.

  • Co-founder & CEO

    18 years of experience developing tech to improve genetic tests. He developed a biothreat detection system for the BioWatch Program (U.S. Dept of Homeland Security). At QuantaLife, he helped launch ddPCR - acquired by Bio-Rad for $162M.

  • VP of Business Development

    A veteran of Lonza and serial entrepreneur. Bill founded Sentinel Monitoring, a microbial detection company acquired by Suez (later Veolia). He brings decades of industry experience, trusted relationships, and a proven track record of commercializing microbial detection platforms.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free